Back to News
Market Impact: 0.35
Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Source: globenewswire.com
Healthcare & BiotechRegulation & Legislation
The FDA accepted the NDA for QTORIN™ rapamycin and granted priority review for microcystic lymphatic malformations. The PDUFA target action date is February 28, 2027; the headline reports a review milestone, not an approval.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- South Korea’s KOSPI halts trade after 8% wipeout on AI losses
- U.S. stock futures rise after AI rout batters Wall St; payrolls data in focus
- ’Our phones are exploding’: Goldman Sachs dissects historic Wall Street crash